Rain Oncology Inc

Change company Symbol lookup

Select an option...

RAIN Rain Oncology Inc

ARIZU Arisz Acquisition Corp

OSH Oak Street Health Inc

LESL Leslie's Inc

AAPL Apple Inc

BYM BlackRock Municipal Income Quality Trust

DLA Delta Apparel Inc

PEG Public Service Enterprise Group Inc

WBD Warner Bros Discovery Inc

ERO Ero Copper Corp

Go

Rain Oncology Inc., formerly Rain Therapeutics Inc., is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. The Company’s product candidates include milademetan and RAD52. Its milademetan is an oral small molecule, an inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, loss of an MDM2 regulator, or other mechanisms. RAD52 is focused on the DNA Damage Response (DDR) pathway. RAD52 represents a strategy for patients that may exhibit homologous recombination deficiencies (HRD+), or a loss of function, of several pathway constituents, including BRCA1/2, PALB2, or several others in tumor types frequently characterized by these deficiencies.